版本:
中国

BRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up

May 12 Abeona Therapeutics Inc

* Abeona therapeutics announces top-line data for abo-102 phase 1/2 mps iiia gene therapy trial at asgct

* Abeona therapeutics inc - abo-102 well-tolerated in six subjects through 1100 days follow up with no serious adverse events

* Abeona therapeutics inc- abo-102 well-tolerated in six subjects through 1100 days follow up with no serious adverse events

* Abeona - positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate gag observed in cohort 2

* Abeona therapeutics inc - reduction of disease manifestation observed in decreased liver volume of 14.81% (+/- 1.2%)

* Abeona therapeutics inc - cohort 1 demonstrated stabilized or improved leiter nonverbal iq scores at six months Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐